Date: Friday 25 March,

Time:12.30 – 1.30pm AEDT


Our annual webinar series are part of an ongoing commitment to capacity building. This year’s theme is Industry Insights.

Join us on Friday 25 March for the first webinar of the series, Industry Insights for Academia.

Associate Professor Nathan Palpant and Dr Natalie Diepenhorst will discuss the strengths of collaboration and its ability to accelerate innovation and maximise the reach of research applications into areas of need.

The webinar, which is open to all current ACvA members, will include two 20-minute presentations and a concluding Q&A session.

Nathan Palpant, Associate Professor, Institute for Molecular Bioscience, The University of Queensland

A/Prof Palpant received his B.S. in Biology from Whitworth University, USA. He then completed his PhD at the University of Michigan working on gene therapy of myofilament proteins for treatment of heart failure. Major findings from his work showed that a single amino acid substitution of alanine to histidine in the switch arm of cardiac troponin I was sufficient to protect hearts against severe acidosis as it occurs in the context of ischemic injury.

In 2015, Dr Palpant commenced as a Group Leader at UQ’s Institute for Molecular Bioscience (IMB), where he leads a research team studying the mechanisms underlying cell fate decisions in cardiovascular development. He is also a Heart Foundation Future Leader and Co-Chair of the Heart Foundation’s Queensland Cardiovascular Research Network.

His research interests focus on mechanisms controlling cardiovascular development and disease, drawing on three core themes spanning genomics, cell biology, and cardiac physiology, and draw on national and international clinical and industry partnerships to orient priorities toward translational opportunities that address key areas of unmet need in clinical care and industry discovery pipelines.

Dr Natalie Diepenhorst, Research Fellow and Project Lead, Monash Institute of Pharmaceutical Sciences

Dr Diepenhorst is a Research Fellow and Project Lead at the Monash Institute of Pharmaceutical Sciences. In collaboration with the French pharmaceutical company, Servier, Natalie currently manages a team of researchers to work collaboratively on a therapeutic target to deliver project specific outcomes spanning molecular biology, structural biology, recombinant and native cell pharmacology.

Prior to this, she ran a team to provide CryoEM structural biology support for multiple projects to facilitate rational drug design. She completed her PhD in 2013 at the Florey Neuroscience Institute, where she designed a novel, recombinant protein approach for investigating drug interactions at receptor proteins, specifically investigating interactions occurring at the relaxin family peptide receptor 1 (RXFP1).

Friday 25 March, 12.30 – 1.30pm AEDT REGISTER HERE